In the Journals

New chair of KidneyX steering committee appointed

John R. Sedor , MD, FASN, the Ray W. Gifford, MD, Endowed Chair in Kidney Research at the Glickman Urology and Kidney Institute at Cleveland Clinic, was recently appointed chair of the Kidney Innovation Accelerator, known as KidneyX, Steering Committee.

According to a press release from the American Society of Nephrology, in his new role, Sedor will be a leader in sparking innovation and encouraging investment for the prevention, diagnosis and treatment of kidney disease. He began his term as chair on April 19.

Sedor, also a professor of molecular medicine at Lerner College of Medicine and a member of the Kidney Disease Research Center at Case Western Reserve University, will bring “passion and expertise” as chair, strengthening the partnership between ASN and the HHS, according to Ed Simcox, chief technology officer for HHS.

“Kidney diseases remain in the shadows but are common, debilitating and burdensome on patients, their families and the economy,” Sedor said in the press release. “Unless and until we drive investment and innovation and open the pathways to commercialization for new technologies and therapies, we will live with the status quo. We can no longer wait. KidneyX is the spark to catalyze change.”

Next week, Nephrology News & Issues will be providing live coverage from the KidneyX Summit, including a presentation by Sedor on his vision of kidney disease opportunities and the role of KidneyX. – by Melissa J. Webb

Reference:

www.newswise.com/articles/view/711446/?sc=dwhr&xy=10007438

 

John R. Sedor , MD, FASN, the Ray W. Gifford, MD, Endowed Chair in Kidney Research at the Glickman Urology and Kidney Institute at Cleveland Clinic, was recently appointed chair of the Kidney Innovation Accelerator, known as KidneyX, Steering Committee.

According to a press release from the American Society of Nephrology, in his new role, Sedor will be a leader in sparking innovation and encouraging investment for the prevention, diagnosis and treatment of kidney disease. He began his term as chair on April 19.

Sedor, also a professor of molecular medicine at Lerner College of Medicine and a member of the Kidney Disease Research Center at Case Western Reserve University, will bring “passion and expertise” as chair, strengthening the partnership between ASN and the HHS, according to Ed Simcox, chief technology officer for HHS.

“Kidney diseases remain in the shadows but are common, debilitating and burdensome on patients, their families and the economy,” Sedor said in the press release. “Unless and until we drive investment and innovation and open the pathways to commercialization for new technologies and therapies, we will live with the status quo. We can no longer wait. KidneyX is the spark to catalyze change.”

Next week, Nephrology News & Issues will be providing live coverage from the KidneyX Summit, including a presentation by Sedor on his vision of kidney disease opportunities and the role of KidneyX. – by Melissa J. Webb

Reference:

www.newswise.com/articles/view/711446/?sc=dwhr&xy=10007438